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Abstract
Adeno-associated virus (AAV)-derived vectors are currently the most common type of viral vectors used in gene therapy 
clinical trials. The presence of neutralizing antibodies (NAbs) against wild-type AAVs in the host body is one of the limi-
tations for the successful use of AAV vectors. AAV capsid manipulation, by which recombinant vectors lose their ability 
to interact with NAbs, can help overcome this obstacle. Various methods can be used for this purpose, including directed 
evolution as well as conjugation of certain chemical groups to AAV epitopes. The present review concisely explains the use 
of AAV vectors in the clinic for gene therapy of some diseases, their limitations, and solutions to these limitations.
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Introduction
Monogenic disorders arise from a mutation in a single gene 
on one or two chromosomes, which can lead to impaired 
gene function. There are approximately 5000–8000 mono-
genic diseases that affect about 6% of the population [1]. 
Replacing a defective gene with its functional copy, so-
called gene therapy, can be a solution for such disorders. 
Tremendous strides have been recently made in gene therapy 
for inherited autoimmune disorders, hemophilia, neurode-
generative disorders, and lymphoid cancers, some of which 
received approval in the USA and Europe [2]. Fundamen-
tally, a gene therapy consists of three components, includ-
ing (I) a foreign gene that is transferred, (II) a target cell or 
tissue, and (III) a gene delivery vector. Such a manipulation 
is generally carried out by viral vectors to deliver a func-
tional copy of the missing or defective gene to appropriate 
cells. Adeno-associated virus (AAV) vectors have emerged 
as a safe and efficient gene delivery system for monogenic 
disorders. However, some limitations of the commonly used 
AAV vectors often prevent their extensive application in 
gene therapy. Here, we provide a brief introduction to AAV 
biology, and comprehensively review the development of 
AAV vectors, the obstacles to clinical applications of such 
vectors, as well as circumvent of the obstacles.
The biology of Adeno‑associated viruses (AAVs)
AAV, first isolated in 1965 from adenovirus infections [3], 
is a small (25 nm), nonenveloped virus containing a single-
stranded DNA genome (4.7 kb) which belongs to the genus 
Dependovirus within the family Parvoviridae. There are cur-
rently 12 serotypes of this virus (AAV-1 through AAV-12) 
and over 100 serotypes in human beings and other primates, 
respectively. The genomic analysis of these viruses reflected 
the evolutionary similarity of different serotypes (Fig. 1). 
The similarity among capsid protein sequences derived 
from various AAV serotypes is between 55 and 99% [4]. 
The genome of the virus consists of two inverted repeat 
sequences known as “Inverted Terminal Repeats (ITRs)” 
that flank two open reading frames (ORFs), Rep, and Cap 
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(Fig. 2) [5]. The ITR sequence, which folds into a T-shaped 
structure, is approximately 145 nucleotides and plays a role 
in DNA replication, genome packaging, gene expression, 
and site-specific integration in the chromosome 19. The 
Rep ORF encodes four proteins that play a regulatory role 
throughout the life cycle of AAV. On the other hand, the Cap 
ORF encodes three viral capsid proteins (VP1, VP2, and 
VP3 with molecular weights of 87, 72, and 62 kDa, respec-
tively). VP1, VP2, and VP3 proteins form a 22-nm-diameter 
T = 1 icosahedral symmetrical structure with a 11:10 molar 
ratio. However, there is also evidence that the VP1:VP2:VP3 
ratio can be 1:1:18. One of the viral Cap ORF can generate 
Fig. 1  Evolutionary relation-
ship between different AAV 
serotypes is shown through an 
unrooted phylogenetic tree (a). 
Similarity of different AAV 
serotypes is based on protein 
capsids (b)
A 
B 
AAV
Homology
AAV1 AAV2 AAV3 AAV4 AAV5 AAV6 AAV7 AAV8
AAV1 100
AAV2 83 100
AAV3 87 88 100
AAV4 63 60 63 100
AAV5 58 57 58 53 100
AAV6 99 83 87 63 58 100
AAV7 85 82 85 63 58 85 100
AAV8 84 83 86 63 58 84 88 100
Fig. 2  Genetic pattern of AAV. 
The AVV genome contains a 
variety of ORFs, including rep 
and cap, that codes functional 
proteins (Rep) and virus struc-
ture (Vp)
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three different protein sequences through different mecha-
nisms [6]. In fact, the alternative splicing creates two dif-
ferent types of RNAs: The first one encodes a VP-1 pro-
tein after transcription, while the second one has two start 
codons that encode VP-2 and VP-3 proteins. Approximately 
60 copies (monomers) of various VP proteins participate 
in the formation of capsids. The protein sequences of these 
monomers (VP-1, VP-2, and VP-3) vary in the N-terminal 
regions, while there is no variability in the amino acid resi-
dues in the C-terminal.
The viral capsid binds to host cell receptors, such as 
heparan sulfate (serotype AAV2), and the virus enters cells 
mainly through clathrin-dependent endocytosis [7]. The 
virus can replicate intracellularly in the presence of helper 
viruses such as adenovirus and herpesvirus. Otherwise, 
AAV can establish a latent infection due to integration into 
the host chromosome (Fig. 3) [8]. Because of its nonpatho-
genic nature, AAV did not receive medical attention for dec-
ades. However, its valuable characteristics, including per-
sistence within host cells, the presence of various serotypes 
and nonpathogenicity, make AAV an appropriate vector for 
gene therapy.
AAV viral vectors
Recent studies have shown that gene therapy has stunning 
results for some genetic disorders, including lipoprotein 
lipase deficiency. Importantly, gene therapy for lipoprotein 
lipase deficiency has received approval in Europe. For use 
in gene therapy applications, viral vectors should have sev-
eral features, including the ability to bind and enter the cell, 
successfully deliver transgenes into the cell nucleus, and 
express the transgenes in the nucleus for a long time as well 
as the lack of toxicity. Long-term and sufficient levels of 
gene expression are two main goals for the gene therapy of 
genetic disorders. Currently, most gene therapy strategies are 
genetically engineered using two types of vectors, lentivi-
rus, and AAV (to transfer the gene to stem cells ex vivo and 
post-mitotic cells in vivo, respectively). Despite the great 
success achieved in this field for animal models of various 
diseases, the application of gene therapy in human beings 
has been faced with several problems such as transgene 
inactivation, insertional mutagenesis, and immunotoxicity, 
resulting in limited clinical trials for gene therapy of human 
diseases. However, AAV-derived vectors have almost all of 
the above-mentioned features, currently accounting for the 
most common type of viral vectors used in gene therapy. 
Highlights from the last meeting of the American Society 
of Gene Therapy (ASGT) showed that about half of the gene 
therapy research was carried out using the AAV vectors. 
Nonpathogenicity is considered as one of the most reasons 
why the virus is a favorite in gene therapy. So far, various 
clinical trials have been conducted using AAV vectors for 
a variety of diseases such as cystic fibrosis, Parkinson’s 
Fig. 3  Life cycle of AAV
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disease, Alzheimer’s disease, muscular dystrophy, epilepsy, 
heart failure, joint inflammation, prostate cancer, and hemo-
philia [9, 10]. Table 1 shows some of the clinical trials using 
AAV vectors. Two decades following the initiation of gene 
therapy trials and more than 1000 clinical trials, there is now 
sufficient information regarding gene therapy applications as 
Table 1  Some clinical trials using AAV vectors. (clinicaltrials.gov)
Disease name Serotype Route of administration Clinical trial phase NCT numbers
Hemophilia B FLT180a Intravenous Phase I NCT03369444
AAV8 Intrahepatic Phase I/II NCT00076557
AAV8 Intrahepatic Phase I/II NCT02396342
AAV5 Intravenous Phase I/II NCT03489291
AAV5 Intravenous Phase II NCT01620801
AAV8 Intrahepatic Phase II NCT02484092
SPK-9001 Intravenous Phase I/II NCT03307980
(Spark & Pfizer)
AAV5 (AMT‐060) Intravenous Phase III NCT03569891
(UniQure) 
LPL deficiency AAV1 (AMT-011) Intramuscular Phase II/III NCT01109498
AAV1 Intramuscular Phase II/III NCT00891306
Cystic fibrosis AAV2 Intranasal Phase I NCT00004533
α1 antitrypsin deficiency AAV1 Intramuscular Phase I NCT00430768
AAVrh.10 Intravenous/Intrapleural Phase I/II NCT02168686
AAV1 Intramuscular Phase II NCT01054339
Duchenne muscular dystrophy rAAV2/5 Intramuscular Phase I NCT00428935
rAAVrh74 Intramuscular Phase I NCT02376816
SRP-9001 Intravenous Phase II/III NCT03769116
(Sarepta)
Pompe disease AAV1 Intradiaphragmatic Phase I/II NCT00976352
AAV2/AAV8 Intravenous Phase I/II NCT03533673
Heart failure AAV1 Coronary artery infusion Phase I/II NCT00454818
AAV1 Coronary artery infusion Phase II NCT01643330
AAV1 Percutaneous  Phase II NCT00534703
Parkinson’s disease AAV2 Intracranial Phase I NCT00252850
NCT00229736
NCT00195143
NCT00229736
Rheumatoid arthritis AAV2 Intra-articular Phase I NCT00617032
AAV2 Intra-articular Phase I/II NCT00126724
Neuronal ceroid lipofuscinosis AAV9 Intrathecal Phase I/II NCT03770572
Choroideremia AAV2 Subretinal Phase II NCT03507686
AAV2 Subretinal Phase I/II NCT02341807
AAV2 Subretinal Phase II NCT02553135
AAV2 Subretinal Phase III NCT03496012
Achromatopsia AAV2/AAV8 Subretinal Phase I/II NCT03758404
Inherited retinal dystrophy AAV2 Subretinal Phase III NCT00999609
Leber congenital amaurosis (Spark)
Hemophilia A AAV8 (BAX 888) Intravenous Phase I/II NCT03370172
AAV5 Intravenous Phase I/II NCT03520712
AAV5 Intravenous Phase III NCT03392974
(BioMarin)
Spinal muscular atrophy AAV9 (AVXS-101) Intravenous Phase I NCT02122952
AAV9 (AVXS-101) Intravenous Phase III NCT03505099
(AveXis)
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well as the concern about its safety. Although gene therapy is 
faced with a variety of setbacks, success stories have begun 
to steadily appear in this field. The positive recommenda-
tion for a gene therapy product (Glybera) by the EMA for 
approval in the European Union and the positive trials for 
the treatment of ADA deficiency, SCID-X1, are representa-
tive examples. More importantly, the US Food and Drug 
Administration (FDA) has recently approved gene therapy 
for some diseases. In July 2016, Spark Therapeutics and 
Pfizer Inc. received Breakthrough Therapy Designation 
from FDA, designed to facilitate faster development and 
approval of investigational drugs, for SPK-9001, an AAV 
capsid expressing a codon-optimized, high-activity human 
FIX variant. In addition, in January 2017, uniQure N.V. 
received Breakthrough Therapy Designation from the FDA, 
for AMT-060, its proprietary, investigational gene therapy 
in patients with severe hemophilia B. Furthermore, FDA 
has approved Spark Therapeutics’ LUXTURNA™ (voreti-
gene neparvovec-rzyl), a one-time gene therapy for patients 
with biallelic RPE65 mutation-associated retinal dystrophy. 
AveXis, Inc., a Novartis company, has recently received 
FDA approval for AVXS-101, a gene therapy replacing the 
survival motor neuron 1 (SMN1) gene, which is missing or 
mutated in individuals with spinal muscular atrophy (SMA). 
BioMarin’s clinical trial of gene therapy holds promise for 
patients with hemophilia A. Sarepta Therapeutics, a com-
mercial-stage biopharmaceutical company, focused mainly 
on the discovery and development of precision genetic medi-
cine to treat rare neuromuscular diseases. The company is 
focused primarily on rapidly advancing the development of 
its potentially disease-modifying Duchenne muscular dystro-
phy (DMD) drug candidates. The FDA has recently lifted the 
clinical hold for the Company’s Duchenne muscular dystro-
phy (DMD) micro-dystrophin gene therapy program.
Intravenous injection of the recombinant AAV2/AAV8 
vector carrying factor IX, which encodes a gene for hemo-
philia patients, led to improvement of the disease with the 
lowest side effects in short- [11] and long-term [12] periods. 
Currently, a variety of vectors have been developed for the 
treatment of various diseases using different serotypes of this 
virus. However, the AAV-2 serotype is the most commonly 
used and well-known serotype for vector construction. Vec-
tors derived from AAV serotypes can infect both proliferat-
ing and nonproliferating cells, such as the muscle, brain, ret-
ina, lung, and liver. For example, the AAV8 serotype shows 
increased tropism for hepatic cells. The first report on the 
successful treatment of hemophilia A in mice was performed 
using the AAV8 vector [13]. Building upon this success, the 
AAV8 vector has also been recently used in a clinical trial 
to transfer the factor IX gene to patients with hemophilia B 
[12]. Comparison of AAV2, AAV6, and AAV8 vectors has 
shown that AAV8 transduction into the liver is more effec-
tive than other vectors. In addition, the virus replicates faster 
than other vectors (about 4–10 times more than AAV2), as 
demonstrated in mice [14]. Several studies have recently 
examined the transduction rate of AAV8 vectors in large ani-
mal models such as monkeys and dogs, demonstrating that 
the transduction rate in these models is lower than that previ-
ously reported in mice [15, 16]. However, the dog models of 
hemophilia were able to consistently express the transgene at 
normal levels after transduction with the AAV8 vector [17]. 
Successful gene therapy using the AAV vectors has also 
been achieved in the clinic for a variety of diseases. How-
ever, the presence of neutralizing antibodies (NAbs) against 
the wild-type AAV in the host body is considered as one of 
the limitations to use AAV vectors. It has been shown that 
more than 70% of the humans were infected with at least one 
serotype of the virus, resulting in the presence of AAV-NAbs 
in the previously infected population [18]. These antibodies 
bind to and prevent viral vectors from entering the target 
cell, thereby leading to reduced expression of transgenes in 
the target cells and, ultimately, reduced efficiency of gene 
therapy. In the primary clinical trial in which the AAV vec-
tor was transferred through the bloodstream, a very low 
level of NAbs (titer 17:1) was found to be able to completely 
eliminate a large amount of vectors (2 × 1012 vg/kg). Stud-
ies in mice and nonhuman primates have shown that the 
1:5 titer of NAbs can completely prevent liver transduction. 
In contrast to circulating anti-AAV2 antibodies, circulat-
ing anti-AAV5 and AAV8 antibodies are less common in 
humans [18]. Subclass analysis of anti-AAV antibodies has 
shown that most of these antibodies are IgG1-type antibod-
ies. Nonetheless, there are reports finding a small amount of 
IgG2, IgG3, and IgG4 [19]. The innate immune system is 
generally the body’s first line of defense against viruses, as 
a result of which gene transfer is difficult using viral vectors 
such as adenoviral vectors. However, AAV vectors mediate 
a mild proinflammatory response. Results from clinical trials 
of more than 300 individuals using the AAV vector showed 
no inflammatory response, such as changes in vital signs, 
nausea, and vomiting [20]. Viral capsid manipulation using 
different methods, in which recombinant viruses or vectors 
lose their ability to interact with NAbs, can overcome this 
limitation. Such methods generally include chemical meth-
ods (use of polyethylene glycol), targeted evolution (genetic 
engineering) and in silico methods. It has been recently dem-
onstrated that in silico reconstruction of the viral evolution-
ary lineage yields a potent vector for gene therapy [21].
The small packaging capacity of AAV is another limi-
tation of AAV-based vectors, so that the vector genome 
larger than 5 kb is rarely packaged [22]. This significantly 
limits the application of AAV gene therapy for those dis-
eases requiring a larger therapeutic expression cassette. To 
bypass this issue, a variety of dual-vector strategies have 
been introduced to duplicate the AAV packaging capacity 
[23].
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Development of AAV viral vectors
Since the beginning of the first studies on AAV vector 
design, there was no standard plaque assay to isolate AAV 
virus clones because of the fact that AAV viruses replicate 
only in the presence of helper viruses. This problem was 
solved by Samulski et al. [24] when they realized that the 
AAV virus was only able to replicate in adenovirus-infected 
cells. These findings have allowed scientists to remove some 
parts of the AAV genome, replace these parts with foreign 
DNA, and replicate these recombinant viruses in the pres-
ence of plasmids expressing rep and cap genes [25]. To 
generate recombinant AAV vectors, a transfection method 
using three vectors is used in HEK293 cells expressing E1a 
and E1b genes (Fig. 4). Naturally, a wild-type AAV pro-
duces approximately  105 viral particles within a cell, and 
this rate is lower for AAV recombinant vectors (about  103 
viral particles per cell). This may be due to poor cotransfec-
tion efficiencies and nonoptimal performance of the rep and 
cap genes [10].
Immune responses to AAV vectors
AAV vectors are complex biological therapeutics which 
comprise a viral capsid, DNA genome, and therapeutic 
transgene, each of which has the ability to interact with 
both innate and adaptive immune systems at multiple levels. 
Innate immune responses not only play an important role in 
defending the host against viral infections but also are con-
sidered as the main toxicity feature in the development of 
gene transfer strategies using adenoviral vectors [26]. AAV 
vectors have received more attention as in vivo gene transfer 
vectors because of their highly mild proinflammatory prop-
erties. Nevertheless, there is evidence demonstrating that 
Fig. 4  Production of recom-
binant AAV viruses using 
3-plasmid transfection
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the interactions between AAV vector components and the 
innate immune system determine the fate of gene transfer. 
The single-stranded DNA genome of AAV vectors interacts 
with the innate immune system via Toll-like receptor (TLR) 
9 [27] as well as type I interferon cascade [28]. The capsid 
of AAV serotype 2 (AAV2), in addition to the viral genome, 
may also interact with the innate immune system through 
TLR2 [29]. While these documents demonstrated the innate 
immune recognition of AAV in animals, there is little infor-
mation about the consequences of such interactions in the 
clinical settings, mainly how innate immunity against AAV 
impacts adaptive responses against the recombinant vector. 
Clinical observation of a number of subjects injected with 
AAV has revealed that there is no evidence of acute clini-
cal responses such as changes in vital signs or nausea and 
vomiting [20]. Humoral immunity against wild-type AAV 
is the first defense and one of the most effective barriers to 
successfully deliver systemic genes with AAV vectors. In 
the first clinical trial for hemophilia B, AAV vectors were 
delivered through the bloodstream; despite the presence of 
NAbs, it did not lead to exclusion of subjects from the trial; 
the reason was because it was unclear what level of titers 
would actually block transduction. The study demonstrated 
that relatively low NAb titers were able to completely neu-
tralize large doses of the vector [30].
Manipulation of AAV vectors to neutralize immune 
responses
The main problem with the use of AAV vectors is the pres-
ence of NAbs (against the wild-type AAV) in the host body. 
Such antibodies bind to and prevent viral vectors from enter-
ing the target cell, thereby reducing the transgene expression 
in the desired tissues and, ultimately, the gene therapy effi-
ciency [31]. Up to now, researchers have developed a variety 
of strategies to manipulate AAV capsids for improving the 
AAV tropism to desired tissue or reducing interaction with 
NAbs. This limitation can be addressed through viral capsid 
manipulation using different strategies in which recombinant 
viruses (vectors) lose their ability to interact with NAbs [32]. 
To this end, various strategies can be used which generally 
include directed evolution (using genetic engineering and 
screening in the presence of NAbs) [33], shielding of the 
viral capsid by chemical modification [34, 35], generation 
of novel AAVs by hybridization of various serotypes [36], 
combined genetic and chemical capsid modifications [37], 
as well as capsid epitope mapping followed by site-directed 
of mutagenesis [32, 38].
In order to develop a directed evolution, a variety of ran-
domized mutations are first created in the AAV gene cap 
using a molecular method for mutation generation such as 
Error prone PCR [39] or DNA shuffling [40]. Subsequently, 
a library of recombinant viruses containing different capsid 
sequences is generated using a packaging system (using 
HEK293 cells). In the next step, this set of viruses is sub-
jected to HeLa cells in the presence of NAbs against capsid 
proteins of the wild-type virus to carry out transduction and 
cell entry. This screening test is called transduction inhibi-
tion assay [31]. In fact, viruses that can infect HeLa cells 
and replicate in these cells are those that have not been 
detected by NAbs. After repeating these steps, recombinant 
viruses are obtained with capsids that escape NAbs. After 
these steps, the genomes of such viruses are extracted and 
sequenced to identify the desired mutation (Fig. 5). In this 
method, AAV variants are chosen in the presence of mono-
clonal antibodies or pooled human sera. Such AAV variants 
have mutations on vital neutralizing epitopes.
Another way to obtain reduced binding of NAbs to 
AAV vectors is to attach amino acid residues present on 
the surface of the viral capsids to chemical groups [34, 41, 
42]. Chemical modifications to enhance viral vector gene 
delivery are comprehensively reviewed [42, 43]. By such a 
method, epitopes present on the surface of viral particle cap-
sids are covered and therefore less exposed to NAbs. Chemi-
cal polymers can also be used for this purpose, including 
polyethylene glycol (PEG), poly-N methacrylamide (poly-
HPMA), and some polysaccharides [7, 43]. For example, 
AAV pegylation not only protects viral particles from NAbs 
but also improves the stability of viral vectors and tissue 
tropism [41, 44].
The application of hybrid viruses is another strategy to 
reduce immune responses to AAVs. In a study, Hauck et al. 
[45] characterized a hybrid vector derived from AAV1 and 
AAV2 (AAV-221) for its effectiveness to treat hemophilia B 
in mice. Therefore, combination of different serotypes can 
be a valuable strategy to develop new recombinant vectors 
with improved characteristics.
There are two main approaches that have been utilized 
for epitope mapping on viral capsids; the first one is epitope 
searching, achieved by peptide scanning [46]. The second 
one, a structure biology-based approach, utilizes cryo-
electron microscopy and image reconstruction of AAV cap-
sids interacted with fragment antibodies, which are gener-
ated from monoclonal antibodies, to directly visualize the 
epitopes [47, 48]. After identification of antigenic epitopes 
that interacted with NAbs, it is possible to modify antigenic 
epitopes by site-directed mutagenesis [49]. Recently, Gurda 
et al. conducted a study in which cryo-electron microscopy 
and image reconstruction (cryo-reconstruction) combined 
with molecular biology approaches were used to define an 
antigenic epitope on the AAV8 capsid surface for a NAb. 
This structure-directed strategy for characterizing the anti-
genic regions of AAVs can thus generate useful informa-
tion to help re-engineer vectors that escape host neutrali-
zation and are hence more efficacious [38]. While there is 
a need for further studies to reduce immune responses to 
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AAV vectors, the combination of different molecular, chemi-
cal, and structural biology-based approaches, together with 
depletion of the immune system by some pharmacologicals 
[50], can be an appropriate strategy to escape the virus from 
viral NAbs, resulting in increased clinical efficacy of AAV 
vectors.
Concluding remarks
Over the past several years, there have been studies in 
humans showing the therapeutic potential of in vivo gene 
transfer using AAV vectors. Nevertheless, host anti-capsid 
immune responses serve as a deterrent to therapeutic suc-
cess when it comes to AAV vectors. Therefore, to generate 
a more practical and efficacious gene transfer system using 
the AAV vector system, it is crucial to understand how both 
neutralizing and nonneutralizing antibodies interact with the 
AAV capsid, especially to dominantly identified epitopes. 
Sufficient information about the AAV antigenic structure, 
capsid determinants of tissue tropism as well as transduction 
makes it feasible to design a neutralization-escaping vector 
capable of evading the host antibody immune responses 
while maintaining optimum tissue tropism and transduction 
efficiency. Some approaches to map antigenic epitopes on 
AAV capsids, such as directed evolution, epitope searching, 
and structure biology-based approaches, can be an effective 
tool to pave the road for safe and efficient gene therapies. 
In addition, several studies have recently demonstrated the 
astonishing capability of CRISPR-Cas9 for gene therapy 
in several animal models delivered by AAV vectors [51, 
52]. Combination of the both recombinant AAV vector and 
CRISPR/Cas9 technologies can have significant advantages 
compared with traditional gene therapy and might exten-
sively contribute to the treatment of many diseases in the 
near future.
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